Results 221 to 230 of about 327,203 (311)

Oral glucocorticoid dose patterns and organ damage in systemic lupus erythematosus – a nationwide cohort study

Arthritis &Rheumatology, Accepted Article.
Background Evaluating the relationship between glucocorticoid (GC) exposure and organ damage in systemic lupus erythematosus (SLE) is challenging since GC dose varies over time. It is unclear which exposure time window captures the full impact of GC usage.
Annica Dominicus, Álvaro Gomez, Ngoc V. Nguyen, Karin Blomkvist Sporre, Francesca Faustini, Elisabet Svenungsson, Elizabeth V. Arkema   +6 more
wiley   +1 more source

Myeloid infiltration and epidermal dysregulation characterize cutaneous photosensitivity in systemic lupus erythematosus. [PDF]

Sci Transl Med
Maz MP, Zhang L, Ma F, Gharaee-Kermani M, Klein B, Moallemian R, Nguyen N, Cai Y, Loftus SN, Billi AC, Abernathy-Close L, Ma M, Bogle R, Hurst A, Tsoi LC, Gudjonsson JE, Kahlenberg JM.   +16 more
europepmc   +1 more source

Outcomes of Tapering Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Multicenter Randomized Noninferiority Trial

Arthritis &Rheumatology, EarlyView.
Objective Evidence supporting tapering of biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA) with sustained low disease activity (LDA) remains limited. We evaluated the efficacy and safety of a structured b/tsDMARD‐tapering strategy in patients with RA who had achieved sustained ...
Dong‐Jin Park, Sung‐Eun Choi, Ji‐Hyoun Kang, Jung‐Yoon Choe, Hye‐Soon Lee, So‐Young Bang, Yun‐Hong Cheon, Sang‐Il Lee, Mingyo Kim, Yoon‐Kyoung Sung, Soo‐Kyung Cho, Jae Hyun Jung, Sung Hae Chang, Sung Won Lee, Yeon‐Ah Lee, Seung‐Geun Lee, Hyun‐Sook Kim, Seung‐Ki Kwok, Seung‐Cheol Shim, Shin‐Seok Lee   +19 more
wiley   +1 more source

Narrowband UVB Induced Subacute Cutaneous Lupus Erythematosus Confined to Vitiligo Patches: A Unique Presentation. [PDF]

Photodermatol Photoimmunol Photomed
Herlekar R, Najeeb A, Vinay K, Chatterjee D, Kumaran MS.   +4 more
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Case Report: Anifrolumab for Refractory Cutaneous Lupus Erythematosus: Relapse After Treatment Interruption and Response to Rechallenge. [PDF]

Int J Rheum Dis
Peng Y, Stidham S, Tariq F, Zaheer M.
europepmc   +1 more source

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

SLE Presenting With Unilateral Loculated Pleural Effusion in a Young Hypertensive Female: A Rare Case Report and Literature Review. [PDF]

Clin Case Rep
Tripathi A, Sah U, Shah S, Singh S, Nishad SR.   +4 more
europepmc   +1 more source

Prevalence of pregnancy and birth outcomes following biologic exposure in immune‐mediated inflammatory diseases: A population‐based study

British Journal of Clinical Pharmacology, EarlyView.
Aims Almost 5% of pregnancies are affected by immune‐mediated inflammatory diseases (IMIDs). As treatments become available, understanding their use during pregnancy is important. We aimed to describe maternal, pregnancy and infant outcomes among IMID pregnancies exposed to biologic therapies. Methods Using the Merative™ MarketScan® Commercial Database,
Leah K. Flatman, Lisiane F. Leal, Gabra Nohmie, Anick Bérard   +3 more
wiley   +1 more source